Calando

Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.
The company also said that efforts to integrate its subsidiaries into a single company are underway.

People in the News

Premium

Timothy Triche

The CEO of Calando parent firm Arrowhead Research also said that the RNAi shop has restarted preclinical research and development — a notable departure from events in 2009 when the company stopped all such work and shuttered Calando's lab amid a cash crunch.

People in the News

Premium

John Rossi

Arrowhead's CEO said that the firm wants to accelerate enrollment in the study in order to meet its goal of completing the trial by year end.

As a result, it will be up to the new court to rule on CSHL's allegations that the law firm Ropes & Gray mishandled certain RNAi-related intellectual property stemming from the work of Greg Hannon and maintained improper business relationships with RNAi drug developers.

The companies also converted roughly $8 million in Calando debt it owed Arrowhead into equity.

Calando's management remains optimistic about deals in 2011. But some industry observers expect that it will take years of continued advancement in the RNAi field and a shift in its players' expectations before major deals are consummated.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.